The phase 2b LUX-Lung 7 clinical trial evaluated the use of afatinib vs. gefitinib in treatment-naïve patients with advanced EGFR-mutant NSCLC [19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.